Evidence map›Paper›PMID 42861131›Full record

ArticleExploration (Beijing, China)2026

A Nitric Oxide-Based STING Agonist Nanoadjuvant With ICD-Derived Membrane Antigens Unleashes Robust Antitumor Immunity.

Shuyu Xu, Yang Song, Tianjiao Zhang, Yan Wang, Mengxin Wang, Xinxin Xie, Qingfeng Chen, Xiaolong Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuyu Xu *Beijing Key Laboratory of Ultrasound Targeted Drug Delivery and Frontier Imaging Technology, Department of Ultrasound Peking University Third Hospital Beijing P. R. China.
Yang Song *Department of Ultrasound Medicine, Beijing Chaoyang Hospital Capital Medical University Chaoyang Beijing China.
Tianjiao Zhang *Beijing Key Laboratory of Ultrasound Targeted Drug Delivery and Frontier Imaging Technology, Department of Ultrasound Peking University Third Hospital Beijing P. R. China.
Yan WangDepartment of Ultrasound The First Affiliated Hospital of China Medical University Shenyang China.
Mengxin WangBeijing Key Laboratory of Ultrasound Targeted Drug Delivery and Frontier Imaging Technology, Department of Ultrasound Peking University Third Hospital Beijing P. R. China.
Xinxin XieBeijing Key Laboratory of Ultrasound Targeted Drug Delivery and Frontier Imaging Technology, Department of Ultrasound Peking University Third Hospital Beijing P. R. China.
Qingfeng ChenInstitute of Molecular and Cell Biology Agency For Science, Technology and Research Singapore Singapore.
Xiaolong LiangBeijing Key Laboratory of Ultrasound Targeted Drug Delivery and Frontier Imaging Technology, Department of Ultrasound Peking University Third Hospital Beijing P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advances in nanovaccine development, their efficacy remains hindered by poor antigen presentation, limited antigen repertoire, and suboptimal T cell priming. Immune adjuvants such as polyinosinic-polycytidylic acid (POLY(I:C)) exert antitumor effects by promoting dendritic cell (DC) maturation and stimulating innate immunity, but their efficacy is limited by poor antigen presenting cell (APC) uptake and weak CD8

Indexed as

gas vaccine adjuvantnanovaccinenitric oxidetumor vaccine

Identifiers

PMID42861131
PMCPMC13654190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.